Head-to-head · free

PDS Biotechnology Corporation vs Rocket Pharmaceuticals, Inc.

PDSB vs RCKT — return on capital, cash generation, margins and balance sheet side by side.

PDSB

3 / 4

measures where PDSB leads

RCKT

1 / 4

measures where RCKT leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasurePDSB · FY2025RCKT · FY2025
Revenue—$0
Net income(8.5M)(223.1M)
Revenue growth (yearly, multi-year)——
Free cash flow(27.8M)(190.5M)
Free cash flow margin——
Net cash / (debt)——
ROIC——
Return on equity-244.2%-60.3%
Gross margin——
Operating margin——
Net debt / EBITDA0.31x0.35x

Figures are as reported by each company; latest fiscal year shown.

Where PDS Biotechnology Corporation's cash went (FY2025)

Capital spending
$0
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full PDSB profile →

Where Rocket Pharmaceuticals, Inc.'s cash went (FY2025)

Capital spending
$440000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full RCKT profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons